IMUNON, Inc.

About IMUNON, Inc.

Imunon is an immunotherapy company focused on developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. They create proprietary immunology and DNA-based platforms and products aimed at addressing some of the world's most difficult-to-treat conditions, including cancer and infectious diseases.

Products & Services

DNA-Based Platforms and Products:Proprietary immunology and DNA-based technologies aimed at treating difficult conditions such as cancer and infectious diseases.

Anti-Cancer Nucleic Acid-Based Therapies:Therapies in clinical development targeting cancer through nucleic acid-based approaches.

Nucleic Acid Vaccines:Vaccines for infectious diseases and cancer, with two products in the pipeline offering potential new therapeutic benefits.

Specialties

Immunology DNA-Based Platforms Anti-Cancer Therapies Nucleic Acid Vaccines Cancer Treatment Infectious Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 7000000 MR: - FA: 7.0 million FAN: 7000000	D: 2025-12-30 FD: 2025-12-30	1 investors
2	RT: Equity T: - FT: Equity	A: 4500000 MR: - FA: $4,500,000 FAN: 4500000	D: 2025-07-22 FD: 2025-07-22	-
3	RT: Private Placement T: - FT: Private Placement	A: 3250000 MR: - FA: $3.25 million upfront with up to an additional $6.5 million FAN: 3250000	D: 2025-05-28 FD: 2025-05-28	2 investors
4	RT: Private Placement T: - FT: Private Placement	A: 3250000 MR: - FA: $3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants FAN: 3250000	D: 2025-05-23 FD: 2025-05-23	-
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2024-07-31 FD: 2024-07-31	-
6	RT: Non-dilutive funding from NOL sale T: - FT: Non-dilutive funding from NOL sale	A: 1300000 MR: - FA: $1.3 million FAN: 1300000	D: 2024-03-25 FD: 2024-03-25	-
7	RT: Non-dilutive T: - FT: Non-dilutive	A: 1600000 MR: - FA: $1.6 million FAN: 1600000	D: 2023-01-12 FD: 2023-01-12	-

Registered Direct Offering Latest

2025-12-30

$7.0M

1 investor (Pro only)

Equity 2025-07-22

$4.5M

Private Placement 2025-05-28

$3.2M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stacy R. Lindborg

President, Chief Executive Officer, and Board Director

D

Douglas V. Faller

Chief Medical Officer

K

Khursheed Anwer

Executive Vice President and Chief Science Officer

K

Kim Graper

Chief Financial Officer

K

Kristin Longobardi

Senior Vice President, Strategic Operations

S

Susan Eylward

General Counsel & Corporate Secretary

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

IMUNON, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised